CagriSema vs Epitalon
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CagriSema
CagriSema is a fixed-ratio combination of cagrilintide (a long-acting amylin analog) and semaglutide, developed by Novo Nordisk. By combining two distinct appetite-regulating peptide hormones, CagriSema aims to achieve greater weight loss than semaglutide alone. Phase 3 data showed 22.7% body weight reduction, and an FDA response is expected in 2026.
Full details →Epitalon
Epitalon (Epithalon) is a synthetic tetrapeptide based on the natural peptide epithalamin, produced by the pineal gland. It is primarily studied for its effects on telomerase activation.
Full details →Side-by-Side Comparison
| Aspect | CagriSema | Epitalon |
|---|---|---|
| Mechanism | CagriSema combines two complementary peptide mechanisms: (1) Semaglutide — GLP-1 receptor agonist providing glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and hypothalamic appetite suppression. (2) Cagrilintide — a long-acting analog of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. Amylin activates amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and hypothalamus, providing additional appetite suppression via a distinct neuronal pathway from GLP-1. The combination produces additive weight loss by engaging two independent satiety signaling systems. | Stimulates telomerase production, which can lengthen telomeres on DNA strands. May also regulate melatonin production and circadian rhythms. |
| Typical Dosage | Phase 3 trial doses: cagrilintide 2.4 mg + semaglutide 2.4 mg weekly (fixed combination in a single injection). Dose escalation: start at cagrilintide 0.15 mg / semaglutide 0.25 mg weekly and escalate over 16 weeks to the maintenance dose. Administered as a single injection combining both peptides. | Typical protocols: 5-10mg daily for 10-20 days, repeated 2-3 times per year. |
| Administration | Single subcutaneous injection once weekly, combining both peptides. Pre-filled pen device. Not yet commercially available. FDA response expected 2026. | Subcutaneous or intramuscular injection. Usually administered in cycles rather than continuously. |
| Side Effects | Phase 3 data: nausea, vomiting, diarrhea, constipation (similar profile to semaglutide alone, but some reports suggest modestly higher GI rates). Decreased appetite. Injection site reactions. | Generally well-tolerated. May affect sleep patterns initially. |
| Best For |
Key Differences
Unique to CagriSema:
Unique to Epitalon:
Detailed Analysis
Commonalities
CagriSema and Epitalon are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose CagriSema for Weight Loss, Diabetes Management. Choose Epitalon for Sleep Quality.
Ready to Learn More?
Looking for trusted sources?